Quick Answer
BioRestorative Therapies, Inc. reported Cash and Equivalents of $1.51 million for fiscal year 2025.
BioRestorative Therapies, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.51M | +175.8% |
| 2024 | $547.9K | -38.0% |
| 2023 | $884.4K | -48.4% |
| 2022 | $1.71M | -91.8% |
| 2021 | $21.03M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $602.4K | -59.6% | -61.3% |
| June 30, 2025 | $1.56M | -30.9% | +26.6% |
| March 31, 2025 | $1.23M | +6.2% | +124.3% |
| December 31, 2024 | $547.9K | -38.0% | -63.2% |
| September 30, 2024 | $1.49M | -38.9% | -33.9% |
| June 30, 2024 | $2.25M | +26.3% | +94.6% |
| March 31, 2024 | $1.16M | -37.0% | +30.8% |
| December 31, 2023 | $884.4K | -47.3% | -63.7% |
- BioRestorative Therapies, Inc. showed an increase of +175.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, BioRestorative Therapies, Inc.’s cash and equivalents has declined by 92.8% (from $21.03 million to $1.51 million).
- The most recent figure is from BioRestorative Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: